BBP News and Press, Virtus LifeSci Biotech Products From 07/18/19

By Stephen H. Dover, Executive Vice President, Head of Equities; Aman Gupta, Portfolio Manager, Research Analyst, Franklin Mutual Series; Brian DeChristopher, Research Analyst, Franklin Equity Group; Evan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group; Krzysz...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...

By Andy Acker, CFA and Denny Fish Portfolio Managers Andy Acker and Denny Fish explore disruptive forces in healthcare and technology. Disruption is being felt across industries and geographies and proving to be a differentiator in the long-term performance of investors' portfolios. Su...

Array BioPharma is  up 56%  after agreeing to a sale to Pfizer for more than $10B. UniQuire, meanwhile, is  higher by 8.35%  after a weekend report that it's exploring a sale. More news on: BioMarin Pharmaceutical Inc., bluebird bio, Inc., Sage Therapeutics, Inc., H...

By Tony DeSpirito Markets tend to focus on one risk at a time, and it’s fragile U.S.-China relations that are front and center now. New blog contributor Tony DeSpirito offers up two potential takeaways for equity investors. Headlines over the U.S.-China trade dispute have been p...

The Healthcare sector ranks fifth out of the 11 sectors as detailed in our Q2'19 Sector Ratings for ETFs and Mutual Funds report. Last quarter , the Healthcare sector ranked seventh. It gets our Neutral rating, which is based on an aggregation of ratings of the 325 stocks in the Healthcare ...

By Marshall Gordon and Nicholas Wu, PhD Healthcare stocks normally react to political rhetoric, but the speed and magnitude of the recent correction in the sector have been surprising. Despite bipartisan clamoring for broad changes to the healthcare system and the Trump administration'...

With yet another US Senate hearing having been held in late February , prescription drug prices have been continuously receiving a lot of attention. While an eventual solution to brand name pricing may take a number of years, changes to the generic industry may be coming quicker. Over the pas...

The Healthcare sector ranks seventh out of the 11 sectors as detailed in our Q1'19 Sector Ratings for ETFs and Mutual Funds report. Last quarter , the Healthcare sector ranked third. It gets our Neutral rating, which is based on an aggregation of ratings of the 323 stocks in the Healthcare ...